不同剂量和疗程伐昔洛韦治疗带状疱疹的多中心随机双盲对照研究

目的：比较不同剂量和疗程伐昔洛韦治疗带状疱疹的疗效和安全性。方法：选择带状疱疹患者为研究对象，采用多中心、随机、双盲、对照的临床试验。试验组患者采用伐昔洛韦1000mg每日3次口服，共服7d；对照组患者采用伐昔洛韦300mg每日2次口服，共服10d。用药后第3、6和10天观察疗效和不良反应。结果：共入组128例，全分析集（FAS）分析128例，符合方案集（PPS）分析118例。治疗后第3、6和10天，试验组和对照组患者的症状、体征积分下降值及有效率比较差异无统计学意义（P〉0．05）；疼痛视觉模拟评分法（visnal analogue scale，VAS）值比较，两组间差异无统计学意义（P〉0．05），但入组时疼痛VAS值≥8的患者，FAS集分析显示，在治疗后第6、10天VAS值下降两组均存在统计学差异（P〈0．05）；PPS集分析显示治疗后第10天VAS值下降，两组间存在统计学差异俨〈0．05）。试验组和对照组不良反应发生率分别为17．18％和12．50％．主要为嗜睡和恶心。结论：增加伐昔洛韦用量治疗带状疱疹安全、有效，与较低剂量伐昔洛韦组相比，对疼痛程度较严重的患者能更显著地减轻疼痛。     

新型纳米根管充填材料对成骨细胞生长的影响

通过体外培养的成骨细胞,采用二甲基噻唑二苯基四唑溴盐比色法和流式细胞术对新型纳米根管充填材料(nHA-PA66)作用下的成骨细胞生长情况的变化进行研究,评价其对成骨细胞生长的影响。以该材料的细胞培养基浸提液作用于实验组细胞,对照组采用培养基本身。实验组和对照组成骨细胞的生长情况和细胞周期无显著性差异,表明该新型纳米材料对成骨细胞的生长和细胞周期无不良影响。提示新型纳米根管充填材料的成骨细胞相容性较好,具有用作根充材料的基础。     

A preliminary study of radioimmunoimaging by 131I-COC183B2 monoclonal antibody in patients with epithelial ovarian cancer.

Monoclonal antibody 131I-COC183B2, developed in our laboratory and proved to fit for human treatment was injected intraperitoneally or subcutaneously in 13 patients. In 8 cases with i.p. injection the disease corresponded with the image, i.e. 3 primary ovarian epithelial cancers showed positive images, 1 ovarian Krukenberg tumor was negative and the other 4 negative images included 1 uterine myoma and 3 ovarian teratomas. In the subcutaneous injection group, 4 cases had ovarian carcinoma, surgery and chemotherapy. Two negative images corresponded with the clinical status-in good health, another negative case had metastatic left supraclavicular lymph node due to ovarian mucinous adenocarcinoma. The last negative image in this group was a case of benign ovarian teratoma which was proved after surgery. The 1 positive case was waiting to be proved by a scheduled third operation. The computer scintigram calculation of T/NT was 5.35 to 13.7. The results suggest that this monoclonal antibody can be used for radioimmunoimaging for the localization of ovarian carcinoma, which is not only helpful for clinical staging and differential diagnosis but is also a good follow-up method.

     

与甲壳素缝线体外复合培养大鼠成肌细胞株L6细胞的形态学

目的：探讨甲壳素作为骨骼肌组织工程支架材料的可行性。 方法：实验于2002-06／12在南方医科大学应用解剖学研究所完成。大鼠成肌细胞株L6与甲壳素医用缝合线体外复合培养。倒置相差显微镜下观察细胞的形态和排列情况。并分别在体外复合培养的第1，2，3，4，5，6天，取出细胞支架复合体，扫描电镜观察成肌细胞的形态和排列情况。 结果：①扫描电子显微镜观察显示，甲壳素医用可吸收缝线的表面比较粗糙。②倒置相差显微镜下可见大鼠L6细胞与甲壳素制备的医用可吸收缝合线间黏附良好，细胞沿缝线排列呈现串珠样，并可以见到细胞聚集现象。③扫描电子显微镜观察，接种24h后，细胞主要为圆球形，随后细胞迁移、伸展、并见突起；第3天，成肌细胞主要为梭形，并见融合趋势；4d后，细胞沿材料纵轴排列并相互融合，并见肌小管样结构形成及细胞外基质分泌。 结论：甲壳素具有作为支架以构建组织工程化骨骼肌的潜能，支架的平行排列有助于工程化骨骼肌纤维良好方向性的形成。     

和厚朴酚对D 半乳糖衰老模型小鼠抗氧化作用的研究

衰老是生命的基本特征之一,是个体发育成熟后,随年龄的增长,体内器官、组织和细胞的形态结构逐渐退化,生理功能相应减弱,整体适应能力和抵抗力随之下降等的综合表现.据相关报道目前解释衰老机制的理论或学说达200多种~([1]),自由基致衰老是大家公认机制之一.     

类风湿关节炎伴发抑郁症动物模型的建立

目的：建立类风湿关节炎伴发抑郁症动物模型。方法：以复合造模思路，在采用胶原诱导复制大鼠类风湿关节炎模型基础上，结合孤养法和慢性不可预知的温和应激方法，造成类风湿关节炎伴发抑郁症动物模型。结果：造模后给予行为学测试和下丘脑5-HT、5-HIAA含量测定，模型组大鼠踝关节肿大畸形，关节炎指数增高，蔗糖水饮用量、旷野试验中水平及垂直得分、下丘脑5-HT、5-HIAA含量都明显小于正常组，有非常显著性差异（P〈0．01）。结论：类风湿关节炎伴发抑郁症动物模型关节肿大畸形，关节炎指数增高，呈抑郁状态，兴趣丧失，快感缺乏，运动迟滞等，能充分模拟类风湿关节炎伴发抑郁患者的核心症状，实验重复性较好，是研究类风湿关节炎伴发抑郁的理想模型。     

卫生保健课程教学误区之我见

卫生保健课程是以贯彻＂预防为主＂的方针、实现＂健康为人人,人人为健康＂的一门重要学科。笔者根据数年的教学实践,结合学生的课堂调查结果,总结卫生保健课程教学中常见的误区,以期同行在教学中避免走进误区,更好地为教学服务。     

去甲斑蝥素N-乳糖酰壳聚糖纳米粒的制备及其特性研究

目的 合成N-乳糖酰壳聚糖作为肝靶向载体,制备去甲斑蝥素纳米粒.方法 通过碳二亚胺缩合法制备N-乳糖酰壳聚糖,并以之为载体,采用离子诱导法制备去甲斑蝥素N-乳糖酰壳聚糖纳米粒,以粒径分布、包封率、载药量为综合指标,正交试验设计优化载药纳米粒的制备工艺,并考察其体外释放特性.结果 合成的N-乳糖酰壳聚糖的取代度为8.92%,优化工艺制备的N-乳糖酰壳聚糖载药纳米外观圆整,平均粒径(118.7±8.84)niB,包封率(57.92±0.40)%,载药量(10.38±0.06)%,其体外释药遵循Higuchi方程.结论 半乳糖修饰壳聚糖载药纳米粒具有良好的缓释特性.     

兔骨髓间充质干细胞Ⅱ型胶原表达的实验研究

目的探讨兔骨髓间充质干细胞表达Ⅱ型胶原的实验研究方法。方法利用β1转化生长因子腺病毒表达载体（Ad—TGFβ1）转染兔骨髓间充质干细胞（MSCs），观察转染后的Ⅱ型胶原表达。结果细胞转染后Ⅱ型胶原在免疫印记和免疫组化检测下均呈强阳性表达。结论Ad—TGFβI转染兔骨髓MSCs可使其细胞内Ⅱ型胶原表达阳性。     

Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention.

This study evaluated the safety and efficacy of batroxobin in treating hyperfibrinogenemia for secondary stroke prevention. Patients with ischemic stroke or transient ischemic attack (TIA) were measured for plasma fibrinogen levels. Selected participants had concomitant hyperfibrinogenemia (plasma fibrinogen > or = 3.0 g/l). Patients enrolled between 1 July 2003 and 31 December 2004 were treated with batroxobin; patients enrolled between 1 January 2002 and 30 June 2003 were treated without batroxobin. Batroxobin was administered intermittently via intravenous injection at 3-monthly intervals. Patients in both groups were followed for 1 year. Any cerebrovascular events and suspected adverse events were recorded. In total, 112 ischemic stroke/TIA patients with concomitant hyperfibrinogenemia were enrolled, 52 being treated with batroxobin and 60 without batroxobin. Six patients (11.5%) with batroxobin and 16 patients (26.7%) without batroxobin had recurrent cerebral ischemic events during follow-up. Stroke/TIA recurrence in patients without batroxobin was higher than that in patients with batroxobin (P < 0.05). Two patients with batroxobin and two patients without batroxobin developed hemorrhagic stroke during follow-up. There were five deaths (9.6%) in the batroxobin group, and seven deaths (11.7%) in the nonbatroxobin group during follow-up (P > 0.05). Intermittent intravenous injection of batroxobin can efficiently reduce the risk for stroke/TIA recurrence in patients with concomitant hyperfibrinogenemia.